Prognostic Predictors for the efficacy of Immune Checkpoint Inhibitors

Prognostic Predictors for the efficacy of Immune Checkpoint Inhibitors - Prognostic Predictors for the efficacy of Immune Checkpoint Inhibitors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053613

Enrollment

250

Registered

2024-02-14

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with lung cancer or malignant pleural mesothelioma at the Department of Respiratory Medicine, Juntendo University Urayasu Hospital between January 1, 2009, and December 31, 2025, or patients diagnosed with lung cancer at another institution and referred to our hospital for anticancer treatment (including immune checkpoint inhibitors) and radiation therapy will be selected.

Exclusion criteria

Exclusion criteria: Patients deemed inappropriate for the study by the principal investigator or co-investigators.

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactYukiko Namba

Juntendo University Urayasu Hospital Division of respiratory medicine

yknanba@juntendo.ac.jp0473533111

Outcome results